# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cash and cash equivalents were $95.2 million as of March 31, 2024. Extended cash runway into 2026 with completion of $77.5 mill...
Aquestive Therapeutics (NASDAQ:AQST) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aquestive Therapeutics (NASDAQ:AQST) with a Buy and maintains ...
Piper Sandler analyst David Amsellem initiates coverage on Aquestive Therapeutics (NASDAQ:AQST) with a Overweight rating and...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aquestive Therapeutics (NASDAQ:AQST) with a Buy and maintains ...